GlassScriptPhysician profile
Sue Ellen Bowes
NPI 1285170274
$7,922.63
in general payments reported to CMS, 2019-2025
33 companies · $1,070 in 2025
The $1,070 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,000 · 2022: $1,465 · 2023: $1,782 · 2024: $1,605 · 2025: $1,070.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,423 · Education: $34.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,423.42 |
| Education | $34.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,087.72 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $711.07 | 2021-2025 | Airsupra, Breztri, Tezspire |
| Jazz Pharmaceuticals INC. | $631.29 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $565.16 | 2021-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Genzyme Corporation | $441.68 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $401.53 | 2021-2025 | Glassia |
| Insmed, INC. | $351.24 | 2021-2025 | Arikayce |
| Mylan Specialty L.P. | $344.97 | 2021-2024 | Yupelri |
| Grifols USA, LLC | $332.22 | 2021-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $316.34 | 2021-2025 | Dupixent |
| Amgen INC. | $293.80 | 2022-2025 | Tezspire |
| Actelion Pharmaceuticals US, INC. | $290.44 | 2021-2024 | Uptravi, Opsumit |
| Mallinckrodt Hospital Products INC. | $222.24 | 2022-2025 | Acthar |
| Avadel Cns Pharmaceuticals, LLC | $157.76 | 2024-2025 | Lumryz |
| Inspire Medical Systems, INC. | $131.95 | 2023 | Inspire |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $99.26 | 2021-2022 | |
| United Therapeutics Corporation | $97.18 | 2021-2023 | Tyvaso |
| Baxter Healthcare | $58.20 | 2023 | Hillrom - Life 2000 Ventilation System |
| Axsome Therapeutics, INC. | $43.36 | 2023-2024 | Sunosi |
| Ani Pharmaceuticals, INC. | $40.06 | 2022-2025 | Purified Cortrophin Gel |
| Bayer Healthcare Pharmaceuticals INC. | $39.02 | 2022-2023 | |
| Resmed Corp | $34.18 | 2023 | |
| Paratek Pharmaceuticals, INC. | $28.53 | 2023 | Nuzyra |
| Csl Behring | $27.43 | 2021 | |
| Harmony Biosciences LLC | $24.31 | 2024 | |
| Gilead Sciences, INC. | $22.06 | 2021 | |
| Novartis Pharmaceuticals Corporation | $22.04 | 2021 | |
| Pfizer INC. | $21.65 | 2022 | |
| Irhythm Technologies, INC. | $21.43 | 2024 | Zio Xt Patch, Zio Monitor |
| Viatris Specialty LLC | $20.38 | 2025 | Yupelri |
| Electromed, INC. | $16.27 | 2021 | |
| Phadia US INC. | $15.95 | 2024 | Immunocap |
| Teva Pharmaceuticals USA, INC. | $11.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sue Ellen Bowes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.